The 15 Best Growth Stocks You Can Buy Right Now in 2019

Posted on Monday, March 25th, 2019 by MarketBeat Staff

At the beginning of a bull market, you can almost choose stocks randomly and find yourself a winner. Now that we are entering the ninth year of the current bull market, growth stocks have appreciated considerably and it's becoming far more challenging to find stocks with real opportunities for appreciation.

Growth companies are still largely outperforming their value counterparts in the United States and the rest of the world largely because of low interest rates, improved corporate earnings and global economic growth. Over the last five years, the S&P 500 Growth Index has returned 14.22% per year. During the same time, the S&P 500 Value Index returned just 12.94%.

Now that the bull market is now nearly a decade old, stocks have become very expensive. Value investors are largely sitting on the sidelines and growth investors are having a hard time figuring out where the remaining growth opportunities exist.

If you are looking for growth stocks in an increasingly small field, we have identified the 10 best growth stocks to buy right now based on their expected earnings growth over the next several years. These companies are all growing rapidly and will likely see double-digit earnings growth next year.

#1 - BioMarin Pharmaceutical (NASDAQ:BMRN)

2019 EPS Estimate: $0.02
2020 EPS Estimate: $1.08 (+5,300.0%)
Stock Price: $87.52
P/E Ratio: -265.2
Consensus Rating: Buy
Ratings Breakdown: 13 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $114.2107 (30.5% Upside)

BioMarin Pharmaceutical logoBioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.

#2 - Targa Resources (NYSE:TRGP)

2019 EPS Estimate: $0.03
2020 EPS Estimate: $0.90 (+2,900.0%)
Stock Price: $40.13
P/E Ratio: 200.6
Dividend Yield: 8.94 %
Consensus Rating: Buy
Ratings Breakdown: 14 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $55.55 (38.4% Upside)

Targa Resources logoTarga Resources Corp., together with its subsidiary, Targa Resources Partners LP, owns, operates, acquires, and develops a portfolio of midstream energy assets in North America. It operates in two segments, Gathering and Processing, and Logistics and Marketing. The company engages in gathering, compressing, treating, processing, and selling natural gas; storing, fractionating, treating, transporting, and selling natural gas liquids (NGL) and NGL products, including services to liquefied petroleum gas exporters; gathering, storing, terminaling, and selling crude oil; and storing, terminaling, and selling refined petroleum products. It is also involved in the purchase and resale of NGL products; and wholesale of propane, as well as provision of related logistics services to multi-state retailers, independent retailers, and other end-users. In addition, the company offers NGL balancing services; and transportation services to refineries and petrochemical companies in the Gulf Coast area, as well as purchases, markets, and resells natural gas. The company operates approximately 27,000 miles of natural gas pipelines, including 37 owned and operated processing plants; and owns or operates a total of 39 storage wells with a gross storage capacity of approximately 69 million barrels. As of December 31, 2017, it leased and managed approximately 640 railcars; 130 transport tractors; and 18 company-owned pressurized NGL barges. The company was founded in 2005 and is headquartered in Houston, Texas.

#3 - Neurocrine Biosciences (NASDAQ:NBIX)

2019 EPS Estimate: $0.13
2020 EPS Estimate: $3.11 (+2,292.3%)
Stock Price: $83.84
P/E Ratio: 382.0
Consensus Rating: Buy
Ratings Breakdown: 15 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $102.5594 (22.3% Upside)

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

#4 - Deutsche Bank (NYSE:DB)

2019 EPS Estimate: $0.09
2020 EPS Estimate: $0.61 (+577.8%)
Stock Price: $8.11
P/E Ratio: -13.5
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 10 Hold Ratings, 7 Sell Ratings.
Consensus Price Target: $8.50 (4.8% Upside)

Deutsche Bank logoDeutsche Bank Aktiengesellschaft provides investment, financial, and related products and services to private individuals, corporate entities, and institutional clients worldwide. It operates through three segments: Corporate & Investment Bank (CIB), Private & Commercial Bank (PCB), and Deutsche Asset Management. The company's CIB segment offers financial market products, such as bonds, equities and equity-linked products, exchange-traded and over-the-counter derivatives, foreign exchange, money market instruments, and structured products. This segment also offers commercial banking, mergers and acquisitions, debt and equity advisory and origination, and cash management services; and trade finance and securities services. Its PCB segment offers payment and current account services, investment and insurance products, deposits, and credit and financing products; mid-cap related products; customized wealth management and investment solutions consisting of discretionary portfolio management, investment advices, and currency and deposit services; start-up and structured financing; interest rate and currency management services; and postal and non-banking services. This segment also offers financing solutions, such as real estate, single-stock, and aircraft financing; and mergers and acquisitions, pre-IPO, private placements, private and public investment solutions, structured lending, and trading and hedging products. In addition, the PCB segment provides wealth structuring, wealth transfer, and philanthropy services. Its Deutsche Asset Management segment invests in equities, fixed income, liquidity, real estate, infrastructure, private equity, and sustainable investments; and delivers alpha and beta solutions. As of December 31, 2017, the company operated 2,425 branches in 60 countries. Deutsche Bank Aktiengesellschaft was founded in 1870 and is headquartered in Frankfurt am Main, Germany.

#5 - Mizuho Financial Group (NYSE:MFG)

2019 EPS Estimate: $0.06
2020 EPS Estimate: $0.37 (+516.7%)
Stock Price: $3.10
P/E Ratio: 7.8
Dividend Yield: 3.27 %
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

Mizuho Financial Group logoMizuho Financial Group, Inc., together with its subsidiaries, engages in banking, trust, securities, and other businesses related to financial services in Japan, the Americas, Europe, and Asia/Oceania. It operates through five segments: Retail & Business Banking Company, Corporate & Institutional Company, Global Corporate Company, Global Markets Company, and Asset Management Company. The company provides deposit products; syndicated, housing, and card loans; business matching services; and advisory services related to overseas expansions, and mergers and acquisitions-related services. It also offers consulting services, including asset management and asset succession; payroll services; and sells lottery tickets issued by prefectures and ordinance-designated cities. In addition, it offers financial solutions, such as bonds, mergers and acquisitions advisory, etc. for corporate customers to meet their needs in fund-raising, investment management, and financial strategies; solutions based on their capital management, business strategy, and financial strategy; solutions related to real estate; advisory services and solutions, such as advice on proposals on various investment products to financial institutions; and financial services that include funding support and public bonds underwriting. Further, the company offers sales and trading services to meet risk hedging and investment needs; investment products for individual customers; and consulting services for institutional investors. Additionally, the company provides products and services related to trust, securitization and structured finance, pension, and stock transfers; securities services; and research, private banking, and information technology-related services. As of March 31, 2018, its branch network included 465 Mizuho Bank, 60 Mizuho Trust and Banking, and 275 Mizuho Securities; and 7,200 ATMs in Japan. The company was founded in 2003 and is headquartered in Tokyo, Japan.

#6 - Mercadolibre (NASDAQ:MELI)

2019 EPS Estimate: $0.39
2020 EPS Estimate: $2.37 (+507.7%)
Stock Price: $491.10
P/E Ratio: -598.2
Consensus Rating: Hold
Ratings Breakdown: 8 Buy Ratings, 4 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $425.6667 (-13.3% Upside)

Mercadolibre logoMercadoLibre, Inc. hosts online commerce platforms in Latin America. It offers MercadoLibre Marketplace, an automated online commerce service for businesses and individuals to list items and conduct their sales and purchases online in a fixed-price or auction-based format. The company's Marketplace platform enables commerce through online classifieds for motor vehicles, vessels, aircraft, services, and real estate; and Internet users to browse through various products that are listed on its Website and to register with MercadoLibre to list and purchase items and services. It also provides MercadoLibre Classifieds service that enables users to list their offerings related to motor vehicles, vessels, aircraft, real estate, and services outside the Marketplace platform; and MercadoPago, an integrated online payments solution to facilitate transactions on and off the MercadoLibre Marketplace by providing a mechanism that allows its users to send and receive payments online. In addition, the company offers MercadoLibre Advertising platform, which enables large retailers and various other consumer brands to promote their products and services on the Internet by providing branding and performance marketing services; and advertisers to place text, display, or banner advertisements in order to promote their brands and offerings on its Webpages and associated sites. Further, it provides MercadoShops, a software-as-a-service, hosted online store solution that enables users to set-up, manage, and promote their own Webstores; and MercadoEnvios, a shipping service for marketplace users. The company was founded in 1999 and is headquartered in Buenos Aires, Argentina.

#7 - Noble Energy (NYSE:NBL)

2019 EPS Estimate: $0.19
2020 EPS Estimate: $0.92 (+384.2%)
Stock Price: $23.89
P/E Ratio: 26.4
Dividend Yield: 1.84 %
Consensus Rating: Buy
Ratings Breakdown: 20 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $38.9650 (63.1% Upside)

Noble Energy logoNoble Energy, Inc., an independent energy company, engages in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids worldwide. It owns, operates, develops, and acquires domestic midstream infrastructure assets in the DJ and Delaware Basins. It principal projects are primarily located in the US unconventional basins and various global offshore conventional basins. As of December 31, 2017, the company had approximately 1,965 million barrels oil equivalent of total proved reserves. Noble Energy, Inc. was founded in 1932 and is headquartered in Houston, Texas.

#8 - GALAPAGOS NV/S (NASDAQ:GLPG)

2019 EPS Estimate: ($1.03)
2020 EPS Estimate: ($4.98) (+383.5%)
Stock Price: $96.28
P/E Ratio: -37.7
Consensus Rating: Buy
Ratings Breakdown: 11 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $125.10 (29.9% Upside)

GALAPAGOS NV/S logoGalapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106; and Evotec AG for the novel target for fibrosis and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

#9 - Nomura (NYSE:NMR)

2019 EPS Estimate: $0.10
2020 EPS Estimate: $0.40 (+300.0%)
Stock Price: $3.63
P/E Ratio: 6.4
Dividend Yield: 1.22 %
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: N/A

Nomura logoNomura Holdings, Inc. provides various financial services to individuals, corporations, financial institutions, governments, and governmental agencies worldwide. It operates through three segments: Retail, Asset Management, and Wholesale. The Retail segment offers various financial products and investment services for individuals and corporations. As of March 31, 2018, this segment operated a network of 156 branches. The Asset Management segment engages in the development and management of investment trusts, including low risk/low return products and high risk/high return products, as well as products for various investor needs; and provision of investment advisory services to public pension funds, private pension funds, governments and their agencies, central banks, and institutional investors. The Wholesale segment is involved in the research, sale, trading, agency execution, and market-making of fixed income and equity-related products. It also engages in underwriting various securities and other financial instruments, such as various stocks, convertible and exchangeable securities, investment grade debts, sovereign and emerging market debts, high yield debts, structured securities, and other securities; arranging private placements, as well as other capital raising activities; and the provision of financial advisory services on business transactions comprising mergers and acquisitions, divestitures, spin-offs, capital structuring, corporate defense activities, leveraged buyouts, and risk solutions. In addition, this segment offers various financial instruments that include equity securities, debt securities, investment trusts, and variable annuity insurance products for the short, medium, and long-terms. The company was formerly known as The Nomura Securities Co., Ltd. and changed its name to Nomura Holdings, Inc. in October 2001. Nomura Holdings, Inc. was founded in 1925 and is headquartered in Tokyo, Japan.

#10 - Alteryx (NYSE:AYX)

2019 EPS Estimate: $0.06
2020 EPS Estimate: $0.24 (+300.0%)
Stock Price: $80.02
P/E Ratio: -400.3
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $79.3636 (-0.8% Upside)

Alteryx logoAlteryx, Inc. operates a self-service data analytics software platform that enables organizations to enhance business outcomes and the productivity of their business analysts. Its software platform includes Alteryx Designer for data preparation, blending, and analytics that could be deployable in the cloud and on premise; Alteryx Server, a secure and scalable server-based product for scheduling, sharing, and running analytic processes and applications in a Web-based environment; Alteryx Connect, a collaborative data exploration platform for discovering information assets and sharing recommendations across the enterprise; Alteryx Promote, an analytics model management product for data scientists and analytics teams to build, manage, monitor, and deploy predictive models to production; and Alteryx Analytics Gallery, a cloud-based collaboration offering that allows users to share workflows in a centralized repository. The company also provides technical support, instruction, and customer services. Alteryx, Inc. was founded in 1997 and is headquartered in Irvine, California.

#11 - National-Oilwell Varco (NYSE:NOV)

2019 EPS Estimate: $0.20
2020 EPS Estimate: $0.79 (+295.0%)
Stock Price: $26.26
P/E Ratio: -328.3
Dividend Yield: 0.75 %
Consensus Rating: Hold
Ratings Breakdown: 11 Buy Ratings, 14 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $38.8333 (47.9% Upside)

National-Oilwell Varco logoNational Oilwell Varco, Inc. designs, manufactures, and sells systems, components, and products for oil and gas drilling and production worldwide. It operates in three segments: Wellbore Technologies, Completion & Production Solutions, and Rig Technologies. The Wellbore Technologies segment offers various equipment and technologies used to perform drilling operations. It also provides solids control and waste management equipment and services; drilling fluids; portable power generation products; drill and wired pipes; drilling optimization and automation services; tubular inspection, repair, and coating services; rope access inspection, instrumentation, and measuring and monitoring services; downhole and fishing tools; steerable technologies; hole openers; and drill bits. The Completion & Production Solutions segment provides equipment and technologies for hydraulic fracture stimulation, including pressure pumping trucks, blenders, sanders, hydration units, injection units, flowline, and manifolds; well intervention, such as coiled tubing units, coiled tubing, and wireline units, as well as blowout preventers and tools; onshore production comprising fluid processing systems, composite pipes, surface transfer and progressive cavity pumps, and artificial lift systems; offshore production that include fluid processing systems, floating production systems, and subsea production technologies; and connectors for conductor pipes. The Rig Technologies segment offers substructures, derricks, and masts; cranes; jacking systems; pipe lifting, racking, rotating, and assembly systems; mud pumps; blowout preventers; drives and generators; rig instrumentation and control systems; mooring, anchor, and deck handling machinery; and pipelay and construction systems. It also provides spare parts, repair, and rentals, as well as remote equipment monitoring, technical support, field service, and customer training services. The company was founded in 1862 and is based in Houston, Texas.

#12 - Tesla (NASDAQ:TSLA)

2019 EPS Estimate: $1.64
2020 EPS Estimate: $6.05 (+268.9%)
Stock Price: $259.44
P/E Ratio: -45.4
Consensus Rating: Hold
Ratings Breakdown: 13 Buy Ratings, 9 Hold Ratings, 15 Sell Ratings.
Consensus Price Target: $325.8788 (25.6% Upside)

Tesla logoTesla, Inc. designs, develops, manufactures, and sells electric vehicles, and energy generation and storage systems in the United States, China, Netherlands, Norway, and internationally. The company operates in two segments, Automotive, and Energy Generation and Storage. The Automotive segment offers sedans and sport utility vehicles. It also provides electric vehicle powertrain components and systems to other manufacturers; and services for electric vehicles through its company-owned service centers, Service Plus locations, and Tesla mobile technicians. This segment sells its products through a network of company-owned stores and galleries. The Energy Generation and Storage segment offers energy storage products, such as rechargeable lithium-ion battery systems for use in homes, commercial facilities, and utility grids; designs, manufactures, installs, maintains, leases, and sells solar energy systems to residential and commercial customers; and sell renewable energy to residential and commercial customers. The company was formerly known as Tesla Motors, Inc. and changed its name to Tesla, Inc. in February 2017. Tesla, Inc. was founded in 2003 and is headquartered in Palo Alto, California.

#13 - ServiceNow (NYSE:NOW)

2019 EPS Estimate: $0.35
2020 EPS Estimate: $1.14 (+225.7%)
Stock Price: $239.29
P/E Ratio: 1,200.7
Consensus Rating: Buy
Ratings Breakdown: 23 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $231.7407 (-3.2% Upside)

ServiceNow logoServiceNow, Inc. provides enterprise cloud computing solutions that define, structure, manage, and automate services for enterprises worldwide. The company offers service management solutions for customer service, human resources, security operations, and other enterprise departments. It operates ServiceNow platform that provides workflow automation, electronic service catalogs and portals, configuration management systems, data benchmarking, performance analytics, encryption, and collaboration and development tools. The company also provides information technology (IT) solutions, such as IT service management product suite for enterprise's employees, customers, and partners; IT operations management that connects a customer's physical and cloud-based IT infrastructure with applications and platforms; and IT business management product suite that enables customers to manage their IT priorities. In addition, it offers customer service management product for customer service cases and requests; human resources service delivery product; and security operations product for security operations management requirements of third-party. Further, the company provides professional services, training services and certification programs, and customer support services. It serves enterprises in various industries, including financial services, consumer products, IT services, healthcare, government, education, and technology. The company sells products through its direct sales team, as well as indirectly through third-party channels by partnering with systems integrators, managed services providers, and resale partners. The company was formerly known as Service-now.com and changed its name to ServiceNow, Inc. in May 2012. ServiceNow, Inc. was founded in 2004 and is headquartered in Santa Clara, California.

#14 - ICICI Bank (NYSE:IBN)

2019 EPS Estimate: $0.21
2020 EPS Estimate: $0.65 (+209.5%)
Stock Price: $10.97
P/E Ratio: 34.3
Dividend Yield: 0.38 %
Consensus Rating: Buy
Ratings Breakdown: 2 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

ICICI Bank logoICICI Bank Limited, together with its subsidiaries, provides banking and financial services in India and internationally. It operates through Retail Banking, Wholesale Banking, Treasury, Other Banking, Life Insurance, General Insurance, and Others segments. The company offers savings, salary, pension, current, and other accounts; and fixed, recurring, and security deposits. It also provides home, car, two wheeler, personal, gold, and commercial business loans, as well as loans against securities and other loans; business loans, such as working capital finance, term loans, collateral free loans, loans without financials, finance for importers and exporters, and secured loans for credit card swipes, as well as loans for new entities, and schools and colleges; and credit, debit, prepaid, travel, and corporate cards. In addition, the company offers life, health, travel, car, two wheeler, home, and student medical insurance products; pockets wallet; fixed income products; investment products, such as mutual funds, gold monetization schemes, and initial public offerings, as well as other online investment services; and farmer finance, tractor loans, and micro banking services, as well as other services to agri traders and processors, and agri corporates. Further, it provides portfolio management, trade, foreign exchange, locker, private and NRI banking, and cash management services; family wealth and demat accounts; commercial banking, investment banking, capital markets and custodial, project and technology finance, and institutional banking services, as well as Internet, mobile, and phone banking services. Additionally, the company offers securities investment, broking, trading, and underwriting services; and merchant banking, private equity/venture capital fund management, trusteeship, and pension fund management services. As of March 31, 2018, it had a network of 4,867 branches and 14,367 ATMs. ICICI Bank Limited was founded in 1955 and is based in Mumbai, India.

#15 - Insulet (NASDAQ:PODD)

2019 EPS Estimate: $0.24
2020 EPS Estimate: $0.71 (+195.8%)
Stock Price: $97.36
P/E Ratio: 1,949.2
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $101.6364 (4.4% Upside)

Insulet logoInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.





More on MarketBeat
15 Stocks that Insiders Love15 Stocks that Insiders Love
20 "Past Their Prime" Stocks to Dump From Your Portfolio20 "Past Their Prime" Stocks to Dump From Your Portfolio
8 Battered Growth Stocks Worth Another Look8 Battered Growth Stocks Worth Another Look
8 Stocks That Are on Sale Right Now8 Stocks That Are on Sale Right Now
9 Low-Risk Stocks for Risk-Averse Investors9 Low-Risk Stocks for Risk-Averse Investors
7 Technology Stocks That Will Lead the Sector in 20197 Technology Stocks That Will Lead the Sector in 2019
7 Dow Jones Stocks That Are Still Laggards7 Dow Jones Stocks That Are Still Laggards





Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel